104 Participants Needed

RO7017773 for Autism Spectrum Disorder

Recruiting at 36 trial locations
RS
RS
Overseen ByReference Study ID Number: BP41316 https://forpatients.roche.com/
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called RO7017773 to see if it can help people aged 15-45 with Autism Spectrum Disorder (ASD) who have a certain level of intelligence. The study will check how well the drug works, how safe it is, and how the body handles it.

Will I have to stop taking my current medications?

The trial requires that your current treatment regimens be stable for 8 weeks before screening and remain stable during the study. If you are taking any prohibited medications or herbal remedies, you must stop them at least 6 weeks before randomization.

Research Team

CT

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Eligibility Criteria

This trial is for individuals aged 15-45 with Autism Spectrum Disorder (ASD), who score at least 50 on the WASI-II intelligence test, have a BMI of 18.5 to 40 kg/m2, and experience autism symptoms. Participants must have a supportive caretaker and be able to follow study procedures without undue risk.

Inclusion Criteria

I know my height in inches.
Your body mass index (BMI) falls within the range of 18.5 to 40 kg/m2.
You have trouble making eye contact or other symptoms associated with autism.
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either placebo or a fixed dose of RO7017773 for approximately 12 weeks

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 weeks

Treatment Details

Interventions

  • RO7017773
Trial Overview The trial tests RO7017773's effectiveness and safety compared to a placebo over 12 weeks in treating ASD. It will also look into how the body processes the drug.
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: RO7017773 Low DoseExperimental Treatment1 Intervention
Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
Group II: RO7017773 High DoseExperimental Treatment1 Intervention
Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive placebo matched to RO7017773 for approximately 12 weeks.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security